Researcher's Profile


     ORCID Follow


Research Outline      2014-10-03 14:09:26

  1. Clinical development of epidermal growth factor tyrosine kinase inhibitors in EGFR mutation positive lung cancer patients, including gefitinib, erlotinib, afatinib and AZD9291, CO1686, etc.
  2. Combination of EGFR TKI with agents targeting at cMET, antiangiogenesis agents, other growth inhibitors, monoclonocal antibodies and signal pathway inhibitors.
  3. HSP90 inhibitors for rare lung cancer mutation positive patients.
  4. Molecular characterization by tissue, blood or plasma samples in lung cancer patients.
  5. Basic research on the resistance pattern and acquired resistance for patients treated with targeted agents. 
  6. New drug development strategy and plans for cancer treatment.